Ceribell vs Kestra Medical Technologies
Kestra Medical Technologies reported revenue of $95 million in fiscal 2026, about the same as Ceribell's $89 million in fiscal 2025. Ceribell's revenue grew 36.1% in its latest year, and Kestra Medical Technologies' grew 59.0%. Ceribell had an operating margin of -65.6%, against -141.6% at Kestra Medical Technologies. Free cash flow was −$42 million at Ceribell and −$117 million at Kestra Medical Technologies. Their fiscal years end in different months (December 31 and April 30), so the periods don't line up exactly.
Side by side
| Ceribell | Kestra Medical Technologies | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Apr 30, 2026 |
| Revenue | $89M | $95M |
| Revenue growth | 36.1% | 59.0% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 87.9% | 51.4% |
| Operating margin | −65.6% | −141.6% |
| Net margin | −60.0% | −138.4% |
| Free cash flow | −$42M | −$117M |
| Free cash flow margin | −46.7% | −122.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 205.8% | 120.4% |
| Last close | $26.14 | $28.64 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CeribellKestra Medical Technologies
Operating margin
Percent of revenue
CeribellKestra Medical Technologies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CeribellKestra Medical Technologies
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ceribell and Kestra Medical Technologies pages.